Ocumetics Advances Bionic Lens Development with Preclinical Study
Calgary, Alberta -- January 10, 2022 -- NewsGenie -- Ocumetics Technology Corp. (TSXV:OTC) has provided an update on its Bionic Lens, an intraocular lens designed to eliminate the need for corrective lenses. Preclinical studies, which began on October 22, 2021, are progressing in three stages.
The first stage, completed in October 2021, tested the lens retainer's structural integrity and ease of insertion. Design improvements were finalized in December 2021 based on the data obtained. Stages 2 and 3 are scheduled to begin February 25, 2022, and March 25, 2022, respectively, with research reports expected in June 2022. Stage 2 will test the retainer with a standard cataract lens, while Stage 3 will test the retainer and Bionic Lens optic element together.
“Our research team has planned three stages of preclinical studies to test the two components of the Bionic Lens technology - the retainer and the optic element,” said Dr. Mark Lee, President & CEO of Ocumetics. “Each of these components is considered a stand-alone medical device, which will be tested separately to meet regulatory approval requirements.”
Dr. Lee added that invaluable data from Stage 1 was used to refine the design to enhance lens functioning and streamline the surgical procedure.
Following successful preclinical studies, Ocumetics plans to begin Phase 1 human clinical trials with a Proof-of-Concept study in the Fall of 2022.
Ocumetics Technology Corp. specializes in adaptive lens designs and is focused on its Bionic Lens technology. The Bionic Lens is designed to allow the eye’s natural muscle activity to shift focus from distance to near.